Chuang L, Burke T W, Tornos C, Marino B D, Mitchell M F, Tortolero-Luna G, Levenback C, Morris M, Gershenson D M
Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Gynecol Oncol. 1995 Aug;58(2):189-93. doi: 10.1006/gyno.1995.1208.
The surgical staging scheme for uterine corpus cancer adopted in 1988 by the International Federation of Gynecology and Obstetrics assigns patients with tumor spread to retroperitoneal lymph nodes to stage IIIC. However, a recommended approach to the detection of lymph node metastasis is not delineated. As part of an ongoing project to assess the value of surgical staging procedures, we reviewed the techniques of lymph node evaluation in 295 at-risk patients. Cases included clinical stage I patients whose preoperative biopsies demonstrated grade 2 or 3 adenocarcinoma or papillary serous, clear cell, or mixed carcinoma. We arbitrarily divided the retroperitoneal space into 10 lymphatic zones: left and right para-aortic, common iliac, external iliac, hypogastric, and obturator. Eighty-two percent of patients had some type of node sampling that involved a mean of three zones. Thirty-three of 244 sampled cases (13.5%) had nodal metastases: 20 had gross involvement and 13 had microscopic. We stratified patients into three groups: (1) those who had no node sampling (n = 51), (2) those with some nodes biopsied (n = 193), and (3) those whose node sampling included a minimum of one para-aortic plus at least one right and left pelvic specimen (n = 51). Retroperitoneal recurrences thought to originate from lymph node sites were identified for the "node-negative" patients in each group: Group 1, 4/51 (8%); Group 2, 9/173 (5%); and Group 3, 0/38 (0%). Lymphatic site failures were seen in 8 of 33 (24%) patients with biopsy-proven metastases. We found that failure to systematically sample pelvic and para-aortic nodes results in a small, but real, risk of undetected extrauterine metastasis. A selective approach to sampling that includes biopsy from both para-aortic and bilateral pelvic lymphatic zones appears to provide an accurate estimate of true node negativity. Further evaluation of this approach is warranted.
国际妇产科联合会于1988年采用的子宫体癌手术分期方案将肿瘤扩散至腹膜后淋巴结的患者归为IIIC期。然而,并未明确推荐检测淋巴结转移的方法。作为一项正在进行的评估手术分期程序价值项目的一部分,我们回顾了295例高危患者的淋巴结评估技术。病例包括术前活检显示为2级或3级腺癌或乳头状浆液性癌、透明细胞癌或混合癌的临床I期患者。我们将腹膜后间隙任意划分为10个淋巴区域:左右腹主动脉旁、髂总、髂外、下腹和闭孔。82%的患者进行了某种类型的淋巴结取样,平均涉及3个区域。244例取样病例中有33例(13.5%)发生淋巴结转移:20例为肉眼可见受累,13例为显微镜下受累。我们将患者分为三组:(1)未进行淋巴结取样的患者(n = 51),(2)进行了部分淋巴结活检的患者(n = 193),(3)淋巴结取样至少包括一个腹主动脉旁标本以及至少一个左右盆腔标本的患者(n = 51)。在每组的“淋巴结阴性”患者中均发现了被认为起源于淋巴结部位的腹膜后复发:第1组,4/51(8%);第2组,9/173(5%);第3组,0/38(0%)。在33例经活检证实有转移的患者中,有8例(24%)出现了淋巴部位复发。我们发现,未能系统地对盆腔和腹主动脉旁淋巴结进行取样会导致未检测到子宫外转移的风险虽小但确实存在。一种包括从腹主动脉旁和双侧盆腔淋巴区域进行活检的选择性取样方法似乎能准确估计真正的淋巴结阴性情况。有必要对这种方法进行进一步评估。